XML 60 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Divestitures (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Nov. 29, 2022
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Assets held for sale   $ 198.3 $ 230.3    
Other Nonoperating Income (Expense)   69.9   $ (33.7)  
Licensing Agreements          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Write down of intangible assets   32.0 172.9    
Upjohn Distributor Markets | Disposal Group, Held-for-Sale, Not Discontinued Operations          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Asset Impairment Charges     374.2    
Inventory Valuation Reserves     9.2    
Loss Contingency, Asset Impairment, Disposal Transactions Not Completed In Current Fiscal Year   250.0      
Assets held for sale   198.3      
Upjohn Distributor Markets | Disposal Group, Held-for-Sale, Not Discontinued Operations | Inventories          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Asset Impairment Charges     84.3    
Upjohn Distributor Markets | Disposal Group, Held-for-Sale, Not Discontinued Operations | Emerging Markets (2)          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Goodwill, Impairment Loss     $ 117.0    
Biocon Biologics          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Other Nonoperating Income (Expense)   $ 45.7      
Biocon Biologics | Scenario, Forecast | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Divestiture of Business, Deferred Cash Consideration.         $ 335.0
Biocon Biologics | Disposal Group, Disposed of by Sale, Not Discontinued Operations          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Disposal Group, Including Discontinued Operation, Consideration $ 3,000.0        
Proceeds from Divestiture of Businesses 2,000.0        
Noncash or Part Noncash Divestiture, Amount of Consideration Received $ 1,000.0        
Disposal Group, Including Discontinued Operation, Ownership Percentage in Disposed Asset 12.90%        
Disposal Group, Including Discontinued Operation, Transition Services Agreement, Revised Term 2 years        
Disposal Group, Including Discontinued Operations, Contingent Consideration Liability, Working Capital Adjustment $ 250.0